Genital mycotic infections with canagliflozin @ and @mg were evaluated in Population @ ( N = @ ; mean exposure -LSB- weeks -RSB- : canagliflozin , @ ; placebo , @ ) , including patients from four placebo-controlled studies , and Population @ ( N = @ ; mean exposure -LSB- weeks -RSB- : canagliflozin , @ ; control , @ ) , including patients from eight placebo/active-controlled studies ( including older patients and those with renal impairment or high cardiovascular disease risk ) .